title: Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.
abstract: OBJECTIVE
  Next-generation sequencing (NGS) allows for high-throughput sequencing analysis of large regions of the human genome. We explored the use of targeted NGS for simultaneous testing for multiple mutations in thyroid cancer.
  
  
  METHODS
  A custom panel (ThyroSeq) was designed to target 12 cancer genes with 284 mutational hot spots. Sequencing was performed to analyze DNA from 228 thyroid neoplastic and nonneoplastic samples including 105 frozen, 72 formalin-fixed, and 51 fine-needle aspiration samples representing all major types of thyroid cancer.
  
  
  RESULTS
  Only 5-10 ng of input DNA was sufficient for successful analysis of 99.6% of samples. The analytical accuracy for mutation detection was 100% with the sensitivity of 3%-5% of mutant allele. ThyroSeq DNA assay identified mutations in 19 of 27 of classic papillary thyroid carcinomas (PTCs) (70%), 25 of 30 follicular variant PTCs (83%), 14 of 18 conventional (78%) and 7 of 18 oncocytic follicular carcinomas (39%), 3 of 10 poorly differentiated carcinomas (30%), 20 of 27 anaplastic (ATCs) (74%), and 11 of 15 medullary thyroid carcinomas (73%). In contrast, 5 of 83 benign nodules (6%) were positive for mutations. Most tumors had a single mutation, whereas several ATCs and PTCs demonstrated two or three mutations. The most common mutations detected were BRAF and RAS followed by PIK3CA, TP53, TSHR, PTEN, GNAS, CTNNB1, and RET. The BRAF mutant allele frequency was 18%-48% in PTCs and was lower in ATCs.
  
  
  CONCLUSIONS
  The ThyroSeq NGS panel allows simultaneous testing for multiple mutations with high accuracy and sensitivity, requires a small amount of DNA and can be performed in a variety of thyroid tissue and fine-needle aspiration samples, and provides quantitative assessment of mutant alleles. Using this approach, the point mutations were detected in 30%-83% of specific types of thyroid cancer and in only 6% of benign thyroid nodules and were shown to be present in the majority of cells within the cancer nodule.
authors: Division of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261. nikiforovye@upmc.edu.
authors: Marina N
authors: MN
authors: Nikiforova
authors: Abigail I
authors: AI
authors: Wald
authors: Somak
authors: S
authors: Roy
authors: Mary Beth
authors: MB
authors: Durso
authors: Yuri E
authors: YE
authors: Nikiforov
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000235:genetics* / Q000473:pathology; D044963:Biopsy, Fine-Needle; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology; D018278:Carcinoma, Neuroendocrine; D002291:Carcinoma, Papillary; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D059014:High-Throughput Nucleotide Sequencing / Q000379:methods* / Q000592:standards; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology; D017354:Point Mutation; D015203:Reproducibility of Results; D000077273:Thyroid Cancer, Papillary; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000473:pathology
references: Am J Med. 1992 Oct;93(4):359-62
references: 1415298
references: N Engl J Med. 2012 Aug 23;367(8):705-15
references: 22731672
references: Diagn Mol Pathol. 2013 Mar;22(1):28-34
references: 23370430
references: Cancer Res. 2003 Apr 1;63(7):1454-7
references: 12670889
references: Thyroid. 2006 Jan;16(1):47-53
references: 16487013
references: J Clin Endocrinol Metab. 2003 May;88(5):2318-26
references: 12727991
references: Am J Clin Pathol. 2003 Jul;120(1):71-7
references: 12866375
references: J Clin Invest. 1993 Apr;91(4):1753-60
references: 8473515
references: J Clin Endocrinol Metab. 2008 Jan;93(1):278-84
references: 17989125
references: JAMA. 2006 May 10;295(18):2164-7
references: 16684987
references: Am J Surg Pathol. 2006 Feb;30(2):216-22
references: 16434896
references: J Clin Endocrinol Metab. 2010 Dec;95(12):5296-304
references: 20826580
references: Nat Rev Cancer. 2013 Mar;13(3):184-99
references: 23429735
references: J Clin Endocrinol Metab. 2012 Feb;97(2):517-24
references: 22170714
references: Nat Rev Cancer. 2006 Apr;6(4):292-306
references: 16557281
references: Endocr Relat Cancer. 2008 Dec;15(4):1069-74
references: 18719091
references: Nat Rev Genet. 2010 Jan;11(1):31-46
references: 19997069
references: Endocr Pract. 2004 Jan-Feb;10(1):31-9
references: 15251619
references: J Mol Diagn. 2009 Nov;11(6):543-52
references: 19815694
references: J Clin Invest. 1993 Jan;91(1):179-84
references: 8423216
references: Cancer. 2000 Dec 25;90(6):335-41
references: 11156516
references: Clin Biochem Rev. 2011 Nov;32(4):177-95
references: 22147957
references: Endocr Rev. 2006 Aug;27(5):535-60
references: 16849421
references: Oncogene. 2004 Sep 23;23(44):7436-40
references: 15273715
references: J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7
references: 16835280
references: Oncogene. 2003 Jul 17;22(29):4578-80
references: 12881714
references: Cancer Res. 2005 Nov 15;65(22):10199-207
references: 16288007
references: J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16
references: 18492751
references: Cancer. 2007 Dec 25;111(6):508-16
references: 17999413
references: Nucleic Acids Res. 2012 Jul;40(Web Server issue):W452-7
references: 22689647
references: J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8
references: 19318445
references: Nat Rev Endocrinol. 2011 Aug 30;7(10):569-80
references: 21878896
references: Clin Cancer Res. 2007 Feb 15;13(4):1161-70
references: 17317825
references: Arq Bras Endocrinol Metabol. 2007 Jul;51(5):654-71
references: 17891229
references: Thyroid. 2006 Feb;16(2):109-42
references: 16420177
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
references: 20952405
references: Endocr J. 2009;56(6):791-8
references: 19550078
references: World J Surg. 2010 Nov;34(11):2589-94
references: 20703476
references: J Clin Endocrinol Metab. 2002 May;87(5):1941-6
references: 11994321
references: Am J Clin Pathol. 2011 Oct;136(4):527-39
references: 21917674
references: Diagn Mol Pathol. 1994 Mar;3(1):9-14
references: 8162258
references: Cancer Res. 1992 Mar 1;52(5):1369-71
references: 1737400
references: Cancer Res. 2009 Jun 1;69(11):4885-93
references: 19487299
references: Cancer Res. 1997 Nov 1;57(21):4710-3
references: 9354427
references: Nat Methods. 2010 Apr;7(4):248-9
references: 20354512
references: J Mol Diagn. 2013 Mar;15(2):171-6
references: 23274167
references: Eur J Cancer. 2007 Mar;43(5):891-900
references: 17289376
references: J Clin Endocrinol Metab. 2011 May;96(5):E863-8
references: 21325462
references: J Clin Endocrinol Metab. 2010 Mar;95(3):1365-9
references: 20130073
references: Nat Med. 2006 Jul;12(7):852-5
references: 16799556
references: Endocr Pathol. 2007 Spring;18(1):1-7
references: 17652794
references: Cancer Cytopathol. 2010 Feb 25;118(1):17-23
references: 20099311
references: Nat Rev Genet. 2010 Oct;11(10):685-96
references: 20847746
references: J Clin Endocrinol Metab. 2011 Nov;96(11):3390-7
references: 21880806
references: Am J Surg. 2003 Dec;186(6):702-9; discussion 709-10
references: 14672783
references: Cancer Lett. 1996 May 15;103(1):57-63
references: 8616809
references: Nat Protoc. 2009;4(7):1073-81
references: 19561590